Adoptive immunotherapy with T lymphocytes expressing transgenic T-cell receptors (TCRs) has shown significant clinical efficacy in various malignant diseases. However, concurrent expression of endogenous and transgenic TCRs in one and the same T cell may impair efficacy and cause safety problems owing to mispairings. The most elegant approach to address these issues is the complete shutoff of the endogenous receptor chains by genome editing. To this end, we designed TCR-α and TCR-β-specific pairs of transcription activator-like effector nucleases (TALENs). TALENs were delivered into T cells using an optimized messenger RNA-electroporation protocol. Based thereon, we obtained precise and highly efficient knockout (KO) in Jurkat (TCR-α: 59.7 ± 4.0%, TCR-β: 37.4 ± 7.3%) as well as primary T cells (TCR-α: 58.0 ± 15.0%, TCR-β: 41.0 ± 17.6%). Moreover, a successive KO strategy for the endogenous TCR chains combined with subsequent transduction of the respective chains of an Influenza virus-specific model TCR led to complete reprogramming of T cells with strongly improved expression and functionality of transgenic TCRs. In conclusion, we have developed novel means for the efficient genome editing in primary T lymphocytes.
INTRODUCTION
Infusion of autologous antigen-specific T cells has become a widely accepted means of adoptive immunotherapy for lifethreatening infections and malignant diseases. [1] [2] [3] In order to obtain sufficiently large numbers of antigen-specific T cells in a reasonable period of time, gene therapeutic approaches based on the introduction of recombinant T-cell receptors (TCRs) or, alternatively chimeric antigen receptors (CARs) 4 have been proposed. Recent clinical studies using redirected T lymphocytes have underlined the enormous potential of such strategies. [5] [6] [7] [8] Whereas TCR-based adoptive immunotherapy requires antigen presentation in the correct human leukocyte antigen context, the use of CARs is limited to surface antigens. 9, 10 Notably, many tumor-specific or at least tumor-associated antigens, such as melanoma antigen E or other cancer-testis antigens, are intracellular proteins and can therefore only be addressed by TCRs. That is why the development of efficient TCR-based strategies has been in the focus of many groups working in the field of cancer immunotherapy.
Importantly, the generation of TCR-transduced T cells for adoptive immunotherapy comprises several critical steps, which are all technically demanding, time-consuming and often errorprone. 11 Using a model of Influenza virus (flu)-specific T cells we recently developed a strategy for the cloning and transfer of recombinant TCRs that addressed several of these challenges. 11 However, even in an optimized setting an ectopically expressed recombinant TCR has to compete with the endogenous TCR expressed by the gene-modified T lymphocyte resulting in impaired expression of the introduced TCR. 9, 11, 12 Moreover, recombinant TCR chains may heterodimerize with their endogenous partner chains. The latter phenomenon called TCR mispairing may not only hamper sufficient surface expression of the transgenic TCR, but also lead to the generation of 'artificial' receptors with novel specificities including autoreactivity. 9, [11] [12] [13] In a mouse model, TCR mispairing was shown to induce lethal graft versus host disease.
14 Probably owing to combinations of these hampering factors, initial clinical adoptive immunotherapy studies relying on TCR gene transfer were less successful than expected. 11 Different strategies, such as murinization of human TCRs, 11, [15] [16] [17] inclusion of additional cysteine residues 18, 19 and codon optimization 11, 20, 21 have been developed to lower the risk of TCR mispairing. The most efficient way to prevent TCR mispairing would be based on the functional or even genetic knockout (KO) of the endogenous receptor. To achieve downregulation of the endogenous TCR, RNA interference has been applied. 22 The recent progress in the development of designer nucleases has opened the way to edit the endogenous TCR genes thereby preventing their correct expression. Indeed, Provasi et al. 12 successfully used zinc-finger nucleases (ZFNs) to knock out both endogenous α-and β TCR chains, albeit at low frequencies (o 10%). Gene-edited cells were subsequently lentivirally transduced to express a new TCR targeting Wilms tumor 1 antigen.
Recently, transcription activator-like effector nucleases (TALENs) have been proposed for efficient genome editing. 23, 24 TALENs are considered to mediate genome editing with higher accuracy and based thereon increased efficiency as compared with ZFNs. We developed two TALEN pairs specific for the α chain and the β chain of human TCRs, respectively. We show here that upon mRNA transfection these TALENs facilitate gene disruption of both TCR chains at high frequencies in Jurkat, and, more importantly, primary T cells (α chain: almost 60%, β chain: >40%). TCR-edited T cells were successfully transduced with our flu-specific model TCR resulting in an efficient transfer of specificity.
RESULTS

Design and generation of TCR-specific TALENs
To define appropriate TCR-specific TALEN-target sequences for the constant regions of TCR-α and TCR-β genes, we used the TAL Effector Nucleotide Targeter 2.0 with the guidelines published by Cermak et al. and Doyle et al. 25, 26 From the identified target sites, we selected two suitable target sites for each TCR-α (TALEN-TCR-α1 and TALEN-TCR-α2) and TCR-β (TALEN-TCR-β1 and TALEN-TCR-β2). Two TALEN monomers containing the corresponding TALE-repeat variable di-residues were cloned for all four target sites ( Figure 1) . Importantly, using the Paired Target Finder no off-target hits were detectable for the chosen repeat variable di-residues.
Functionality of TCR-specific TALENs
We next aimed at establishing optimal conditions for the co-transfection of two plasmids via electroporation. To this end, we made use of two reporter plasmids LeGO-iG2 and LeGO-iS2 encoding enhanced green fluorescent protein (eGFP) and T-Sapphire. 27 Approximately 50% of Jurkat cells were successfully co-transfected when 5 μg of each plasmid were used, whereas efficiency increased to about 80% at concentrations of 20 μg per plasmid ( Supplementary Figure 1) , albeit at the cost of cell viability (o 50%, not shown).
To prove functionality of novel TALENs, we applied 20 μg per plasmid to ensure higher transfection rates. After electroporation cells were cultured for 3-4 days under standard cell-culture conditions before they underwent fluorescence-activated cell sorting (FACS) analysis with anti-TCR and anti-CD3 antibodies. We observed markedly decreased TCR and CD3 expression in Jurkat cells transfected with either of the four TALEN pairs as compared with mock-transfected cells (Supplementary Figure 2) . As better results were obtained for TALEN pairs TCR-α2 and TCR-β1, as compared with TCR-α1 and TCR-β2, we focused on these TALENs in subsequent experiments.
Optimized conditions for mRNA transfection in T cells Besides the observed high toxicity of plasmid electroporation (see above), plasmid-transfected cells can be expected to express very high protein levels over relatively prolonged periods of time. Moreover, accidental integration of plasmids might lead to stable long-term expression of the transgene. 28 As high-level as well as long-term TALEN expression are most probably associated with a higher risk for off-site cleavage, short-term expression is favorable. We therefore asked whether messenger RNA (mRNA) transfection would be a reliable alternative for TALEN delivery into T cells.
We first established an optimal electroporation protocol for Jurkat cells. To this end, we used two different concentrations of eGFP-mRNA (2 μg and 5 μg in 600 μl) and applied different conditions (voltage: 200 V, 250 V, 275 V and 300 V; pulse length: 30 ms, 20 ms, 10 ms, 5 ms and 2 ms). eGFP expression was determined after 24 h by flow cytometry. Very efficient transfection (>90%) was obtained with both mRNA concentrations using a square-wave electroporation protocol with 300 V and 20 ms pulse length ( Figure 2) . Notably, at improved efficacy cell viability was much higher (~80%) than for the plasmid transfection ( o50%, not shown). To further improve transfection rates, we increased the amounts of mRNA and assessed eGFP expression levels based on mean fluorescence intensities (MFIs). As illustrated in Figure 2b , MFIs directly correlated with the amount of mRNA electroporated. In striking contrast to plasmid electroporation, increasing the amount of mRNA did not result in any elevation of toxicity. Indeed, cell numbers were even higher in the 20-μg mRNA group as compared with the mock group (not shown).
To further improve transgene expression in electroporated cells, we assessed the impact of hypothermic culture conditions. We found strongly enhanced eGFP levels for cells cultured under hypothermic conditions (32°C for 24 h) as compared TALEN-TCR-β2
T-cell receptor-β-locus (chr. 7q34) TALEN-TCR-β1 TALEN-TCR-β2 TALEN-TCR-β1 TALEN-TCR-β2 We next assessed kinetics of eGFP levels by FACS to verify the transient nature of mRNA-mediated expression ( Figure 2d ). As evident, expression peaked at 24 h and dropped by~50% per day. eGFP was detectable for~7 days after electroporation of 2 and 5 μg mRNA, and up to 10 days for 10 μg mRNA.
Efficient KO of TCR-α and TCR-β chains in Jurkat cells after mRNAmediated TALEN delivery We went on by applying the improved conditions for electroporation to transfer TCR-specific TALENs in Jurkat cells. Successful genome editing was confirmed by flow cytometry with antibodies against the CD3/TCR complex. We first determined optimal mRNA amounts using TALEN-TCR-α2. As illustrated in Figure 3 , we observed a clear correlation between mRNA amounts and CD3/TCR KO peaking at >60% for 20 μg mRNA. No change in the numbers of TCR-expressing cells was found in control groups (mock and electroporation of single TALEN-TCR-α2 right or left arm, respectively) (complete data not shown). Similar results were found for TALEN-TCR-β1, although KO efficiencies were slightly lower for the TCR-β as compared with TCR-α chain (in Figures 3b and c) .
To assess kinetics of TALEN-mediated knockdown of the CD3/TCR complex, we analyzed TCR expression every 24 h for 6 days post transfection. As shown in Figure 3d , already 24 h after electroporation~20% of the Jurkat cells lost TCR surface expression. By 72 h TCR gene KO was completed and numbers of TCR-positive and TCR-negative Jurkat cells did not change further.
TALEN-mediated TCR KO in primary T cells
To adapt the electroporation protocol for primary T lymphocytes, we again first tested an mRNA encoding eGFP. A square-wave protocol using 300 V and 10 ms facilitated transfection of~80% of primary T cells and viabilities above 90% (not shown). Transfection rate (~85%) as well as MFIs were slightly higher using 300 V and 2 pulses of 8 ms, although at the cost of viability (~80%, not shown). These conditions were then used for TALEN transfection. TCR KO was assessed after 3-4 days using TCR-and CD3-specific antibodies and FACS analysis.
Clear-cut loss of TCR-α expression was already detectable at low amounts (2 μg) of TALEN-mRNA, and, as for Jurkat cells, a direct correlation between mRNA amounts and TCR KO was seen. Specific TCR KO increased to~50% with 5 μg and~60% with 10 μg mRNA. No additional increase was found for 20 and 40 μg TALEN-mRNA ( Figure 4a ). Further experiments were performed with 10 μg mRNA. In six independent experiments with primary T lymphocytes from three different donors and TALEN-TCR-α2, a significant increase in the number of TCR-negative cells (58.5 ± 15%) was found as compared with all control transfections (mock: 5.6 ± 1.1%; TALEN-TCR-α2R (right arm only): 3.3 ± 1.1%; TALEN-TCR-α2L: 3.4 ± 1.3%) ( Figure 4b ). As shown by repeated FACS analyses, the KO remained stable over a period of 2 weeks strongly indicating successful genome editing (Figure 4c ). The latter was formally proven by a surveyor assay (Figure 4d ) performed for the cells shown in Figure 4a . Clearly, most efficient genome editing was observed for 10 μg mRNA. Moreover, for the same experiment (10 μg group), we amplified and subcloned the TALEN-TCR-α2 target region. Sequencing revealed genomic deletions in 9 out of the 17 clones (53%) analyzed (Figure 4e ), which is in good agreement with the FACS data above.
We next repeated the same set of experiments with the TALEN-TCR-β1 targeting the TCR-β-locus. Again, TCR KO was already observed with 2 μg mRNA and peaked at 10 μg mRNA (Figure 4f ). On average, 41.0 ± 17.6% KO of the TCR-β was found with 10 μg TALEN-TCR-β1 in six independent experiments using primary T lymphocytes from three different donors (Figure 4g ). TCR KO was thus significantly higher as compared with the three controls (mock, left TALEN arm and right TALEN arm). Again, directed editing of the TCR-β-locus was confirmed by DNA sequencing (not shown). Complete reprogramming of Jurkat cells to express a Flu-specific TCR KO of the endogenous TCR represents the only way to completely prevent mispairing of endogenous with transgenic TCR chains. To achieve this, we utilized a strategy that is based on the subsequent KO of the endogenous TCR chains and the stepwise introduction of their transgenic equivalents ( Figure 5) . This strategy was first tested on Jurkat cells. Following KO of the TCR-β chain, CD3-negative cells were enriched by magnetic cell sorting using Dynabeads to a purity of~99% (Figure 6a ). Sorted cells were transduced with the transgenic Flu-TCR-β chain, which should result in restored CD3 expression on the cell surface. Indeed, numbers of CD3-expressing cells (88.7%) were in good agreement with numbers of Flu-TCR-β-positive (87.0%) cells (Figure 6b , lower panel). In contrast, neither mock transduction nor transduction with the Flu-TCR-α-chain did renew CD3 expression. Transduced, CD3-positive cells were then FACS-sorted and electroporated with TALEN-TCR-α2. Again, CD3-negative cells were enriched using CD3 dynabeads and transduced with the corresponding α-chain of the Flu-TCR (not shown). Jurkat cells now again expressing CD3 could be expected to be completely reprogrammed and to express the transgenic Flu-TCR only. To test this, we used a highly specific Flu-tetramer. Importantly, >80% of the CD3-positive double-KO Jurkat cells indeed bound the tetramer, whereas this number was below 20% for non-edited Jurkat cells (Figure 6c ). Of note, the KO of just one of the two endogenous TCR chains already resulted in increased expression of the transgenic TCR, although only by a factor of 2 ( Figure 6c ).
Finally, we tested functional competence of partially and completely reprogrammed Jurkat cells in an interleukin 2 (IL-2) enzyme-linked immunosorbent assay (ELISA). As shown in Figure 6d , complete KO of the endogenous TCR led to a marked, 14-fold increase in IL-2 production as compared with Complete reprogramming of primary T cells In a final set of experiments, we used the approach outlined in Figure 5 on primary T lymphocytes. As step-wise TCR editing requires relatively long culture periods, we first assessed the capacity of TALEN-treated, CD3-negative T cells to proliferate in vitro upon stimulation with IL-2 or CD3/CD28 beads (Figure 7a) . Over a period of 7 days, we found no significant differences in the expansion rate of TALEN-treated versus untreated (CD3 positive) cells. Interestingly, stimulation of TALEN-treated, CD3-negative T cells with CD3/CD28 beads led to an~20-fold expansion within 7 days, obviously mediated by CD28 signaling (Figure 7a) . Also, stimulation with IL-2 or CD3/CD28 beads and subsequent cell expansion for 7 days did not result in changes in the relative proportion of CD3-positive cells in mixed cultures again indicating that CD3-positive and TALEN-treated, CD3-negative T cells are equally sensitive toward proliferation stimuli. The possibility to restimulate activated T cells in the absence of additional TCR involvement, and the role of CD28-mediated signaling therein should be of interest for T-cell-based immunotherapy strategies and deserve further attention.
Next, primary T cells were activated and TCR-α and TCR-β chains were successively knocked out as described above for Jurkat cells ( Figure 5 ). Using the Flu-specific TCR, we obtained proof-of-principle for complete reprogramming of TCR specificity. 
TALEN-mediated TCR editing
As indicated by tetramer binding, numbers of Flu-specific T lymphocytes increased by a factor of 5 after TALEN-mediated editing of both TCR chains as compared with non-treated T cells transduced with the same TCR (Figure 7b) . Moreover, MFIs reflecting the number of TCR molecules on the cell surface were also higher in fully reprogrammed cells. In contrast, KO of only one of the two endogenous TCR chains resulted only in minimal effects (Figure 7b) .
Finally, we assessed effector capabilities of reprogrammed primary T cells as compared with transduced primary T cells upon antigen contact using interferon-γ and IL-2 ELISAs. As shown in Figure 7c and in good agreement with the tetramer data, u n t r e a t e d interferon-γ secretion was about five times higher for reprogrammed as compared with non-edited, TCR-transduced T cells (P o 0.01), whereas production of IL-2 was even elevated by a factor of 18 (P o0.01). Together, these data provide proof for the successful and efficient reprogramming of primary T cells after TALEN-mediated KO of both endogenous TCR chains.
DISCUSSION
Adoptive immunotherapy with genetically redirected T lymphocytes holds great promise in cancer treatment. 3, [5] [6] [7] [8] 11, 12 Reprogramming of T cells is possible by introducing either novel TCRs or CARs. 9 At the same time, expression of the endogenous TCRs by primary T lymphocytes can not only impair the efficacy of T-cell redirection, [11] [12] [13] but has also been associated with severe side effects, namely graft-versus-host reactions.
14,29 Therefore, various strategies have been supposed to suppress the expression of endogenous TCRs and/or avoid mispairing between transgenic and endogenous TCR chains. [11] [12] [13] 22 The ultimate way to avoid any impact of endogenous TCRs is their genetic disruption to fully exclude surface expression. Recently, Provasi et al. 12 introduced an elegant technique to subsequently disrupt both the endogenous TCR-α and TCR-β chains using ZFNs. They showed that lentiviral vector-mediated expression of a new TCR targeting Wilms tumor 1 antigen after KO of the endogenous TCR loci resulted in fully functional T lymphocytes suppressing growth of Wilms tumor 1-positive tumors in vivo in a mouse model. Moreover, those authors demonstrated strongly reduced alloreactivity of TCRedited T cells as compared with just TCR-transduced T cells. 12 We here followed a similar step-wise strategy to completely edit T-cell specificity, but, in contrast to Provasi et al., 12 we made use of TALENs targeting highly conserved sequences in the constant regions of the endogenous TCR chains. Also, we exploited mRNA transfection for TALEN delivery instead of integrase-defective TALEN-mediated TCR editing B Berdien et al lentiviral vectors as used in that work for ZFN delivery. Gene disruption became evident at the protein level (TCR expression on the cell surface) as early as 24 h and was completed 72 h after mRNA transfection. This is in good agreement with data reported for mRNA injection into the cytoplasm of mouse pronuclear-stage embryos, where gene disruption on the genomic level was found already 12 h post injection. 30 More importantly, the presented mRNA electroporation protocol enabled us to greatly improve efficiency of TCR gene disruption, which in primary T lymphocytes reached~60% for the TCR-α and 40% for TCR-β chains, as compared with o10% obtained with ZFNs. 12 Also, this protocol was associated with very low immediate toxicity even after repeated application.
The method proposed here for genome editing would have several advantages with regard to potential clinical applications. First, production and application of mRNA does not require safety regulations applying to viral vectors or other gene-modified organisms. Second, there is a low risk of random integration for non-integrating vectors such as plasmids, 31 adeno 32 or adenoassociated 33 and even for integrase-defective lentiviral vectors, 34 whereas mRNA mediates only transient expression. 35 Permanent expression of nucleases is obviously associated with an increased risk of genomic instability. Third, TALENs have been reported to combine high efficiency with superior specificity as compared with ZFN, but also novel CRISPR-Cas nucleases. 36, 37 In fact, no potential off-target was identified using the Paired Target Finder. 25 Finally, mRNA transfection of primary T lymphocytes can easily be up-scaled to large-scale good manufacturing practice conditions, as previously shown for the transient transfer of CARs. 38 Although the method for targeted gene disruption proposed here can be expected to strongly reduce the risk of unwanted genotoxic effects, off-target activity cannot completely be ruled out. As there are no known potential off-target sites for the used, highly specific TALENs, quantification of off-target activity will require next-generation-sequencing approaches covering large parts of the genome. Importantly, however, primary T lymphocytes have been shown to be much less sensitive toward genotoxic effects and malignant transformation as compared with hematopoietic stem cells. 39, 40 In the last set of experiments, we used lentiviral transduction of primary and Jurkat T cells with an established Flu-specific model 
TCR
11 to investigate whether TALEN-mediated disruption of endogenous TCR chains indeed results in improved T-cell reactivity. Notably, we observed increased Flu-TCR expression and improved activity even after TALEN-mediated disruption of just one of the endogenous TCR chains in Jurkat as well as primary T cells (complete data not shown). However, functionality of fully reprogrammed T lymphocytes was much higher as compared with both non-edited and single-TCR-chain-edited T cells. As disruption of just one TCR chain would decrease the risk of mispairing only by a factor of 2, full reprogramming seems to be preferable. As shown here, the protocol for generating large numbers of completely TCR-edited T cells required about 2 weeks, which would be compatible with good manufacturing practice production of targeted T cells. It needs to be noted that concurrent KO of both TCR chains to speed up the procedure would not be advisable, as (i) this would be associated with an increased risk of genomic recombination and (ii) identification and sorting of completely edited T cells (based on loss of CD3 expression) would not be possible anymore.
Strategies aiming at a KO of the endogenous TCR might be of particular value in settings of adoptive immunotherapy with genetically redirected allogeneic T cells in order to avoid unwanted graft-versus-host reactions, for example, after stem cell transplantation. Although complete shutdown of both endogenous TCR (α and β) chains is advisable in the context of TCR gene transfer, disruption of just one TCR chain would be sufficient to abrogate potential T-cell allo-or autoreactivity in the context of CAR gene transfer. In the latter case, the whole process of editing and transduction would require about just 1 week.
In conclusion, we have established a TALEN-based method for the highly efficient disruption of both the TCR-α and TCR-β chains of the human TCR. As it is based on mRNA delivery, this technique ensures short-term expression of TALENs thus decreasing the risk of unwanted off-target effects associated with long-term expression. Therefore, our delivery method might be equally suited for research as well as clinical applications. Indeed, the use of mRNA is much more feasible in the context of good manufacturing practice regulation, as its production and application do not require biosafety laboratories. In a proof-of-principle experiment, we have shown a potential application of the presented system, namely the full reprogramming of both Jurkat and primary human T lymphocytes based on TCR disruption and lentiviral transduction with a novel Flu-specific TCR. Redirected T cells were shown to not only display improved expression levels of the transgenic TCR, but also much stronger reactivity against their cognate antigen. We conclude that the system presented here might be very useful in the context of adoptive immunotherapy, but also immunological research.
MATERIALS AND METHODS
Peripheral blood mononuclear cells (PBMCs) and cell lines
PBMCs were isolated by Ficoll gradient centrifugation from blood (buffy coats) donated by healthy individuals after informed consent. For culture and transduction, T cells were activated for 72 h with Dynabeads Human T-Activator CD3/CD28 (Life Technologies, Darmstadt, Germany) according to the manufacturer's instructions and kept in X-VIVO 15, supplemented with 8% autologous plasma and 100 U ml − 1 IL-2. 
TALEN-mediated TCR editing
The T-cell line Jurkat (DSMZ, Braunschweig, Germany, ACC 282) was cultured in RPMI 1640, Glutamax (Life Technologies), supplemented with 10% fetal calf serum, 2% L-glutamine and 1% sodium pyruvate (Life Technologies). The cell line 293T (ATCC CRL-3216, ATCC/LGC Standards, Wesel, Germany) used for virus production and titration of viral supernatants was cultured in Dulbecco's modified Eagle medium, Glutamax (Life Technologies) and supplemented with 10% fetal calf serum.
If not specified otherwise cell culture was performed under standard conditions (37°C, 100% relative humidity, 5% CO 2 ). Cell culture material was purchased from Corning Incorporated (Corning, NY, USA), Greiner Bio One (Frickenhausen, Germany) and Sarstedt (Nürnbrecht, Germany).
Design and cloning of TALENs
TALENs were constructed by fusing DNA-binding domains constructed according to the principle of TALEs derived from Xanthomonas sp. to the catalytic domain of the endonuclease FokI. To facilitate editing of the TCR locus, we designed TALENs binding to the constant regions of the TCR-α and TCR-β chains, respectively. TALEN-target sequences were identified using TAL Effector Nucleotide Targeter 2.0. 25 To detect potential off-target binding of the TALENs, we applied the Paired Target Finder. 25 TALENs were cloned in accordance with the protocol developed by Sanjana et al. 42 In short, we first generated a monomer library containing monomers with specific ligation adapters that are used to define the position of the given monomer in the TALE tandem repeat. In the next step, using Golden-Gate-ligation monomers were joint in the designed order to obtain hexamers. In a second round of Golden-Gate-cloning three hexamers were cloned into the final TALEN vector. Finally, correct identity of TALENs was verified by sequence analysis.
In vitro transcription of mRNA
For mRNA transcription, plasmids were linearized using restriction enzymes (AvrII for TALEN constructs and HindIII for control plasmid pJET-T7-eGFP) and purified using the QIAquick PCR Purification Kit (Qiagen, Hilden, Germany). mRNA in vitro transcription was carried out using T7 mScript Standard mRNA Production System (Biozym, Hessisch Oldendorf, Germany) in accordance with the manufacturer's protocol. The RNeasy Kit (Qiagen) was used for all RNA purification steps (manufacturer's protocol: RNA clean up).
Electroporation of plasmid DNA and mRNA Cells were washed twice and resuspended at a final density of 1-2 × 10 6 / 600 μl in Opti-MEM (Life Technologies). For mRNA, all subsequent steps were performed on ice. mRNA or DNA was transferred into the cuvette and mixed with 600 μl of the cell suspension. Electroporation was performed using a Gene Pulser Xcell Total System (Bio-Rad, Munich, Germany). A square-wave pulse and indicated conditions were applied for mRNA; for DNA 1050 μF, 1000 Ω, 300 V and exponential decay were used. Following electroporation, cells were transferred into 24-well culture plates and incubated for 24 h at 32°C before they were either analyzed or cultured under standard conditions.
Surveyor assay
To confirm gene editing on the molecular level, we performed surveyor assays essentially as described. 42 In short, genomic DNA was isolated from TALEN-treated cells as well as control cells and TALEN-target sequences were amplified by PCR using the following primers (Surv-α2-for: ctctgcatgactcactagcactctat, Surv-α2-rev: gactgactta gtgagctgggaaagat; Surv-β1-C1-for: ctaatatgtgtcactaccccacgag, Surv-β1-C1-rev: gagagttacacaggccacatagaaag; Surv-β1-C2-for: gaggagacatcacctggaa tgttag, Surv-β1-C2-rev: gatatattaggctgtgctctggctct). After purification, 150 ng of the PCR products were denaturated at 98°C for 10 min and cooled down to room temperature (23°C). Reannealed PCR products were incubated for 30 min at 37°C in the presence of 10 U of mismatchsensitive T7 endonuclease (New England Biolabs, Frankfurt, Germany) and analyzed by agarose gel electrophoresis.
Lentiviral TCR gene transfer
Cloning of novel lentiviral LeGO-MP vectors encoding the α or β chain of a Flu-specific TCR was described recently. 11 Vector-containing supernatant was generated by transient transfection of 293T packaging cells as previously. 11, 27 Viruses were pseudotyped with vesicular stomatitis virus glycoprotein for transduction of T-cell lines or with gibbon ape leukemia virus envelope protein for transduction of PBMCs. Vector supernatants were titrated on 293T cells. 43 Jurkat cells were transduced in their respective growth medium by spin infection at multiplicities of infection (MOIs) of 1-2. Briefly 1-2 × 10 5 target cells were incubated with vector-containing supernatant in the presence of 8 μg ml − 1 polybrene (Sigma-Aldrich, St Louis, MO, USA) and centrifuged at 1000 g for 1 h at 22°C.
For transduction of primary human T lymphocytes, non-tissue culturetreated 24-well plates were coated with 20 μg RetroNectin (Takara Bio Inc., Otsu, Shiga, Japan) for 2 h at room temperature or overnight at 4°C. Vector supernatant (MOI: 5-20) was loaded onto the RetroNectin-coated plates by four consecutive centrifugation rounds at 940 g and 4°C for 30 min. Subsequently,~2 × 10 5 preactivated T cells were added per well and incubated under standard cell-culture conditions.
FACS analysis/sorting
Flow cytometry analysis of transfected T-cell lines and PBMCs was conducted at the indicated time points. Transduction efficiencies were assessed at least 72 h after infection. FACS analyses were performed on an LSRFortessa cytometer (Becton Dickinson, Heidelberg, Germany), equipped with 405-/488-/561-and 640-nm lasers. FACS sorting of CD3-positive T lymphocytes was carried out using a FACSAriaIIIu (Becton Dickinson), equipped with 405-/488-/561-and 640-nm lasers. transduced Jurkat or 1 × 10 5 transduced PBMCs, were then cocultured in 96-well round bottom plates in 250 μl culture medium. After 18-20 h the supernatant was harvested and analyzed for interferon-γ and IL-2 secretion using the appropriate Ready-Set-Go! ELISA-Kit (eBioscience, San Diego, CA, USA) following the manufacturer's instructions. Absorbance was measured at 450 nm (minus 570 nm for wavelength correction) using the Sunrise Basic Tecan ELISA Analyzer (Tecan Austria GmbH, Grödig, Austria). Data were analyzed using MyAssays Software (MyAssays Ltd, http://www. myassays.com) and a four-parameter logistic fit curve.
